From the Guidelines
For a Type 1 diabetic using the OmniPod 5 system, the Automated Insulin Delivery (AID) feature should typically be set to "On" to maximize the benefits of this hybrid closed-loop system, as recommended by the latest standards of care in diabetes-2025 1. When activating the OmniPod 5, you should input accurate personal information including weight, total daily insulin dose, and insulin-to-carbohydrate ratios to establish appropriate baseline settings. The system uses SmartAdjust technology to automatically adjust basal insulin delivery every five minutes based on continuous glucose monitor (CGM) readings, working toward a target glucose level. Most adults should start with a glucose target of 110-130 mg/dL, though this can be temporarily adjusted to 110-150 mg/dL for exercise or other situations requiring less aggressive insulin delivery, as part of a comprehensive approach to glycemic management that includes education on matching mealtime insulin doses to carbohydrate intake and fat and protein intake, as well as modifying the insulin dose based on concurrent glycemia, glycemic trends, and anticipated physical activity 1. The AID feature works best when the CGM is consistently providing data, so ensure the Dexcom G6 sensor is properly placed and calibrated. The system needs time to learn your body's insulin needs, so allow 1-2 weeks for it to adapt to your patterns before making major manual adjustments. Even with automated features, you'll still need to bolus for meals and monitor during periods of illness, stress, or unusual activity, highlighting the importance of ongoing education and support in achieving optimal glycemic outcomes and quality of life 1.
Some key considerations for the use of Automated Insulin Delivery systems like the OmniPod 5 include:
- Early use of continuous glucose monitoring to improve glycemic outcomes and quality of life and to minimize hypoglycemia 1
- Regular reevaluation of the insulin treatment plan and insulin-taking behavior to incorporate specific factors that impact choice of treatment and ensure achievement of individualized glycemic goals 1
- Preference for insulin analogs over injectable human insulins to minimize hypoglycemia risk 1
- The importance of automated insulin delivery systems in improving glycemic outcomes and quality of life for adults with type 1 diabetes 1
From the Research
Setting AIY on OmniPod 5 for Type 1 Diabetics
The optimal setting for AIY (Automated Insulin Y) on the OmniPod 5 for individuals with type 1 diabetes can depend on various factors including the individual's glucose targets, age, and prior therapy.
- Studies have shown that using the OmniPod 5 system with customizable glucose targets can lead to favorable glycemic outcomes in both children and adults with type 1 diabetes 2, 3.
- The choice of glucose target can impact the effectiveness of the system, with some studies suggesting that lower targets (e.g., 110 mg/dL) may be associated with better time in range (TIR) outcomes, particularly in certain age groups or populations 2, 3.
- However, the optimal target glucose setting may vary from person to person, and healthcare providers may need to consider individual factors such as age, prior therapy, and health insurance coverage when determining the best approach for a given patient 2.
- Clinical experience and evidence suggest that the OmniPod 5 system can be effective and safe when used with glucose targets ranging from 110 to 150 mg/dL 3, 4.
- Personalizing settings and optimizing glycemic outcomes may involve advanced issues related to the initiation and ongoing optimization of insulin therapy using the system, including how to adjust settings based on individual patient needs and circumstances 4.